Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

@article{Sacco2015CurrentTO,
  title={Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.},
  author={Assuntina G. Sacco and Ezra E. W. Cohen},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2015},
  volume={33 29},
  pages={
          3305-13
        }
}
This review highlights the evidence-based data to support current best management practices for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Current limitations and areas of emerging therapeutics are also emphasized. The cornerstone of palliation for patients with R/M HNSCC is a platinum-based backbone. Platinum doublets induce higher response rates than single agents but do not demonstrate a survival advantage and are associated with increased… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 56 CITATIONS, ESTIMATED 31% COVERAGE

FILTER CITATIONS BY YEAR

2011
2019

CITATION STATISTICS

  • 1 Highly Influenced Citations

  • Averaged 17 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 78 REFERENCES

Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
VIEW 14 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…